Latigo Biotherapeutics Files for Nasdaq IPO, Aims to Bring Sodium-Channel Pain Drug to Market

Latigo Biotherapeutics Inc. announced on July 17 2026 that it has filed a registration statement with the U.S. Securitie...

Read story →